Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"Proton Pump Inhibitor Use and Its Association With Asthma: A Systematic Review and Meta-Analysis","authors":"Ganesh Bushi,&nbsp;Mahalaqua Nazli Khatib,&nbsp;Suhas Ballal,&nbsp;Pooja Bansal,&nbsp;Balvir S. Tomar,&nbsp;Ayash Ashraf,&nbsp;M. Ravi Kumar,&nbsp;Aashna Sinha,&nbsp;Pramod Rawat,&nbsp;Abhay M. Gaidhane,&nbsp;Sanjit Sah,&nbsp;Hashem Abu Serhan,&nbsp;Mahendra Pratap Singh,&nbsp;Muhammed Shabil","doi":"10.1155/jcpt/6643853","DOIUrl":"https://doi.org/10.1155/jcpt/6643853","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Asthma is a prevalent chronic respiratory condition marked by airway inflammation and hyperresponsiveness, significantly impacting quality of life. Emerging evidence suggests a potential association between proton pump inhibitor (PPI) use and an increased risk of asthma. This systematic review and meta-analysis assessed the relationship between PPI use and the development or exacerbation of asthma.</p>\u0000 <p><b>Methods:</b> A systematic search of PubMed, Web of Science, and Embase databases was conducted, covering studies published from the inception of the database to July 12, 2024. Observational studies examining the association between PPI use and asthma risk were included. Two reviewers independently extracted data using Nested Knowledge software, with study quality assessed via the Newcastle–Ottawa Scale. A random-effects meta-analysis was performed, pooling odds ratios (ORs) and hazard ratios (HRs) to assess the association, with heterogeneity evaluated via the <i>I</i>² statistic.</p>\u0000 <p><b>Results:</b> Fourteen studies, conducted between 2009 and 2024 and involving over 1.7 million participants, met the inclusion criteria. The pooled HR showed a 38% increased risk of asthma among PPI users compared to nonusers (HR, 1.38; 95% CI, 1.14–1.62). OR analysis indicated a 29% higher risk (OR, 1.29; 95% CI, 1.23–1.35). PPI users had an 81% higher risk compared to histamine H₂ receptor antagonist (H₂RA) users (HR, 1.81; 95% CI, 1.09–2.53), and asthma patients using PPIs were 61% more likely to experience exacerbations (OR, 1.61; 95% CI, 1.42–1.80).</p>\u0000 <p><b>Conclusion:</b> PPI use is associated with an increased risk of asthma. These findings underscore the need for cautious prescribing and further investigation into underlying mechanisms.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6643853","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the 90% Effective Dose of Remimazolam in Terms of Inhibiting Responses to Upper Gastrointestinal Endoscopy Insertion in Elderly Patients: A Double-Blind Study Utilizing a Biased Coin Up-and-Down Sequential Method","authors":"Chaoliang Zhang,&nbsp;Pengfei Yin,&nbsp;Lufang Zhang,&nbsp;Binwei Hu,&nbsp;Mi Wang,&nbsp;Xianhui Kang,&nbsp;Xian Zhao","doi":"10.1155/jcpt/3966741","DOIUrl":"https://doi.org/10.1155/jcpt/3966741","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Remimazolam is a good option for anesthesia in elderly patients undergoing gastrointestinal (GI) endoscopy procedures because of its rapid onset, short metabolic duration, and extensively documented safety profile. However, the accurate clinical dosage of these agents has yet to be determined. The objective of this research was to examine the efficacy of the 90% effective dose (ED90) of remimazolam in suppressing the responses of elderly patients during the insertion phase of upper GI endoscopy.</p>\u0000 <p><b>Methods:</b> We enrolled 53 individuals aged 65– 85 years who underwent upper GI endoscopy and were anesthetized with an intravenous bolus of remimazolam. After initiating an initial dose of 0.35 mg/kg remimazolam, subsequent adjustments were made on the basis of the patient’s response, employing an up-and-down sequential allocation using a biased coin design. The primary outcome was the ED90 of the remimazolam infusion for inhibiting the response to upper GI endoscope insertion. Adverse reactions during the perioperative period were observed and recorded.</p>\u0000 <p><b>Results:</b> The ED90 of remimazolam for upper GI endoscope insertion in elderly patients was 0.400 mg/kg (95% CI = 0.348–0.524). Stable circulation was maintained in all patients, and no serious adverse events were observed during sedation. Satisfaction levels were high among the participants: Patients reported a satisfaction score of 4.98 ± 0.14 points, anesthesiologists rated their satisfaction at 4.91 ± 0.35 points, and endoscopists expressed a satisfaction level of 4.89 ± 0.38 points (based on a total score of 5 points, with a minimum of 1 point).</p>\u0000 <p><b>Conclusion:</b> Administration of remimazolam for upper GI endoscopy in elderly patients was found to be both safe and effective. A single intravenous bolus at an ED90 dose of 0.556 mg/kg effectively suppressed the response to the procedure.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2200062535</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/3966741","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143513760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center","authors":"Alberto Russi,&nbsp;Camilla Saran,&nbsp;Giulia Zanchetta,&nbsp;Giorgia Zorzetto,&nbsp;Giovanna Crivellaro,&nbsp;Marco Maruzzo,&nbsp;Giulia Pasello,&nbsp;Alessio Fabozzi,&nbsp;Chiara De Toni,&nbsp;Carola Cenzi,&nbsp;Elena Berti,&nbsp;Silvia Cognolato,&nbsp;Francesca Pipitone,&nbsp;Alberto Bortolami,&nbsp;Alice Capogrosso Sansone,&nbsp;Chiara Salvato,&nbsp;Francesca Bano,&nbsp;Ugo Moretti,&nbsp;Paola De Ambrosis,&nbsp;Giovanna Scroccaro,&nbsp;Marina Coppola","doi":"10.1155/jcpt/5572209","DOIUrl":"https://doi.org/10.1155/jcpt/5572209","url":null,"abstract":"<div>\u0000 <p><b>Purpose:</b> Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020-2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs.</p>\u0000 <p><b>Methods:</b> Data from the real-world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression-free survival (PFS) and overall survival (OS).</p>\u0000 <p><b>Results:</b> A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single-agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS.</p>\u0000 <p><b>Conclusion:</b> A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5572209","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL-6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database","authors":"Meilin Fang,&nbsp;Jinglin Li,&nbsp;Boyang Zhuang,&nbsp;Weijie Liang,&nbsp;Ling Wang,&nbsp;Cunze Wang,&nbsp;Wujin Chen,&nbsp;Fangqing Cai,&nbsp;Junshan Ruan,&nbsp;Zhuiliang Huang,&nbsp;Yishun Jin","doi":"10.1155/jcpt/5520102","DOIUrl":"https://doi.org/10.1155/jcpt/5520102","url":null,"abstract":"<div>\u0000 <p><b>Aim:</b> This study aimed to investigate post-marketing adverse events (AEs) of interleukin-6 (IL-6) inhibitors, and to explore risk factors for death.</p>\u0000 <p><b>Method:</b> Disproportionality analyses were conducted on adverse event cases of IL-6 inhibitors reported to the US Food and Drug Administration Adverse Event Reporting System (FAERS) from the time of drug launch until the fourth quarter of 2023. Univariate and multivariate logistic regression analyses were carried out utilizing patient-related clinical information, and prediction models for IL-6 inhibitor-related mortality risk were developed by incorporating patient age and weight factors.</p>\u0000 <p><b>Results:</b> A total of 63,445 reports were retrieved, with the majority of known age groups falling between 18 and 64 years. Most reports were submitted by consumers and physicians, predominantly from the United States. Tocilizumab was associated with AEs such as drug intolerance and infection, while sarilumab showed symptoms of pain and condition aggravated. Siltuximab was linked to disease progression and thrombocytopenia. The median time to AEs with IL-6 inhibitors was 74 days (interquartile range [IQR] 10-311), mostly occurring within 1 month. Factors such as age, propionic acid derivative, infections and infestations, nervous system disorders, and immune system disorders were independent risk factors for deaths related to IL-6 inhibitor use (<i>p</i> &lt; 0.05). The mortality risk prediction model demonstrated good discriminatory power and clinical applicability in both the training set (AUC 0.6968) and the validation set (AUC 0.7502).</p>\u0000 <p><b>Conclusion:</b> Our postmarketing pharmacovigilance analysis revealed the types and incidence of AEs related to IL-6 inhibitors. Column line diagrams may be useful for clinical assessment of the occurrence of death and have high clinical utility.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5520102","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143118132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic Alterations in Renal Clear Cell Carcinoma: A Comprehensive Expression and Clinical Outcome Analysis","authors":"Dafei Weng,&nbsp;Zhenqian Qin,&nbsp;Xuefeng Yuan,&nbsp;Xuping Jiang,&nbsp;Hua Rui","doi":"10.1155/jcpt/5520198","DOIUrl":"https://doi.org/10.1155/jcpt/5520198","url":null,"abstract":"<div>\u0000 <p>Renal clear cell carcinoma (ccRCC) presents a unique landscape of genetic and epigenetic modifications, the understanding of which is crucial for the development of targeted therapies and improved prognostication. This study explores the differential expression of histone-related genes (HRGs) in ccRCC and correlates these findings with patient clinical outcomes. By leveraging the Cancer Genome Atlas (TCGA) data, we performed a robust multidimensional analysis of HRG expression profiles in ccRCC versus adjacent normal tissues. Our results demonstrate a significant upregulation of several key epigenetic regulators, including UHRF1, KDM5A, EZH2, PRDM6, and TWIST1, in tumor samples, with statistical significance suggesting their involvement in tumorigenesis and progression. Paired expression analysis within patient-matched samples confirmed the consistency of overexpression in tumors. The prognostic relevance of these genes was underscored through survival analyses, which revealed a clear stratification of patients into distinct risk categories based on their expression profiles. The integration of these genetic markers with clinical parameters facilitated the development of a predictive nomogram, yielding a quantifiable tool for survival prediction. Our comprehensive analysis elucidates the profound impact of epigenetic dysregulation in ccRCC and proposes a novel set of biomarkers for disease diagnosis, prognostic stratification, and potential therapeutic targeting, marking a significant stride toward precision oncology in renal cancer.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5520198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143113963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Examination of the Association Between Bisphenol-Related Genes and Lung Cancer","authors":"Lin Chen,&nbsp;Min Zhou,&nbsp;Dingliang Lv,&nbsp;Shuiwei Qiu","doi":"10.1155/jcpt/8872458","DOIUrl":"https://doi.org/10.1155/jcpt/8872458","url":null,"abstract":"<div>\u0000 <p>In recent years, the release of substantial amounts of synthetic endocrine-disrupting chemicals (EDCs) into the environment has posed significant threats to human health. Among these EDCs, bisphenol A (BPA) and its substitutes, such as bisphenol S (BPS), bisphenol F (BPF), and bisphenol AF (BPAF), are widely used and have been implicated in disrupting various biological processes. This research aimed to evaluate the potential link between bisphenol-related gene expression and lung cancer prognosis. Using the Comparative Toxicogenomics Database (CTD), we identified genes involved in bisphenol metabolism and their significant associations with key oncogenes and hormone-disrupting pathways, including INS, ESR1, ESR2, AR, MAPK1, MAPK3, PPARG, and CYP19A1. Our Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses indicate that bisphenol-related genes may be associated with a variety of cancers, particularly lung cancer. To develop a risk model, we employed Cox regression and LASSO regression analyses, constructing a prognostic prediction model for lung cancer based on bisphenol-related gene expression (BBPPM). This model demonstrated prognostic significance, with lung cancer patients categorized into high-risk and low-risk groups, revealing significant differences in survival rates and highlighting the model’s accuracy in predicting lung cancer outcomes. In addition to bioinformatics analyses, experimental studies were conducted to evaluate the effect of BPA on lung cancer cell behavior. BPA exposure significantly promoted the proliferation of A549 lung cancer cells, as assessed by the CCK-8 assay, and increased the clonogenic potential of the cells in a colony formation assay.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/8872458","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143113405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrative Analysis of PPAR and Immune Pathways in Hepatocellular Carcinoma: Constructing a Prognostic Risk Model Using TCGA Data","authors":"Jiao Li,&nbsp;Yang Chen,&nbsp;Lei Cao","doi":"10.1155/jcpt/5516378","DOIUrl":"https://doi.org/10.1155/jcpt/5516378","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with its pathogenesis intricately linked to metabolic and immune dysregulation. This study aims to elucidate the molecular mechanisms underpinning HCC by analyzing metabolic and immune-related pathways and constructing a prognostic risk model.</p>\u0000 <p><b>Methods:</b> We utilized data from The Cancer Genome Atlas (TCGA) to analyze genomic and clinical characteristics of HCC. Techniques such as single-sample gene set enrichment analysis (ssGSEA), weighted gene coexpression network analysis (WGCNA), and gene set variation analysis (GSVA) were employed to explore the interplay between metabolic pathways, immune responses, and HCC progression. In addition, a prognostic risk model was developed using univariate Cox regression and LASSO regression analysis based on PPAR signaling and immune-related genes.</p>\u0000 <p><b>Results:</b> Our ssGSEA results indicated a significant involvement of metabolism-related pathways in HCC. The WGCNA identified key immune-related genes, with particular modules correlating with macrophage activity. The prognostic model, comprising five key genes, effectively stratified patients into low- and high-risk groups, with implications for overall survival (OS). Further analyses revealed the model’s correlation with clinical characteristics and immune-related indexes, suggesting its utility in predicting HCC progression.</p>\u0000 <p><b>Conclusion:</b> This study provides a comprehensive molecular portrait of HCC, emphasizing the role of metabolic reprogramming and immune responses. The prognostic model offers potential for personalized therapeutic strategies and improved clinical outcomes. Future research should focus on validating these findings and exploring the therapeutic potential of targeting metabolic and immune pathways in HCC.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2025 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5516378","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143111104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication Errors: An Update From the Central Region of Ghana","authors":"Alex Boye,&nbsp;James Asenso,&nbsp;Philippa Jennifer Ayiku,&nbsp;Wisdom Xoese Kwadzo Agroh","doi":"10.1155/2024/3444425","DOIUrl":"https://doi.org/10.1155/2024/3444425","url":null,"abstract":"<div>\u0000 <p><b>Objective:</b> The study assessed the following medication error indicators: drug education by pharmacists, the clarity of physician prescription forms, patients’ and students’ drug package insert (PI) reading habits, and the adequacy of information on drug PIs.</p>\u0000 <p><b>Design:</b> A cross-sectional study was carried out. One-on-one interviews were conducted with the pharmacists alongside the use of structured questionnaires to assess their involvement in drug education and experience with the clarity of physician prescription forms. A structured questionnaire was used to investigate patients’ and students’ PI reading habits. Drug PIs were collected from pharmacies, and their components were examined based on the World Health Organization’s (WHO) criteria for labeling pharmaceutical products.</p>\u0000 <p><b>Setting:</b> The study was conducted at four selected hospital pharmacies, four community pharmacies, and the University of Cape Coast, in the Cape Coast Metropolis, Ghana.</p>\u0000 <p><b>Participants:</b> The study included pharmacists working at the pharmacies, patients, and students of the University of Cape Coast, who visited any of these pharmacies.</p>\u0000 <p><b>Results:</b> Fifty-three percent of pharmacists educate their patients on drug dosage, storage, and precautions during each patient visit, 17.6% hardly do, and 29.4% do not educate their patients. A majority of the sampled prescription forms submitted by patients to the pharmacists had illegible handwriting (63.7%) and unconventional prescription notations (78.0%). Of the 138 visiting patients, only a few (41.0%) read the PIs before drug use as compared to students (72.9%). Out of the 88 PIs collected, 90.2% had component deficiencies.</p>\u0000 <p><b>Conclusion:</b> Pharmacists’ drug education to visiting patients was poor, just as patients’ PI reading habits. Most PIs had component deficiencies, and the majority of prescription forms had some medication error-provoking features. Going forward, pharmacists, physicians, drug manufacturers, and patients must perform their responsibilities toward the collective effort of minimizing medication errors associated with drug use.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3444425","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synergistic Inhibitory Effect of Gliquidone Against Cisplatin-Resistant Human Lung Adenocarcinoma","authors":"Xi Qiu,&nbsp;Bo Liu,&nbsp;Pan-Pan Ye,&nbsp;Lin-Lin Song,&nbsp;Xue Zhang,&nbsp;Wei-Ping Gu,&nbsp;Ling Li,&nbsp;Shun-Wei Zhu,&nbsp;Wei Zhao,&nbsp;Xin-Mei Yang","doi":"10.1155/2024/7133198","DOIUrl":"https://doi.org/10.1155/2024/7133198","url":null,"abstract":"<div>\u0000 <p>Cisplatin (CDDP) can combat various types of cancers, employing a multifaceted approach against these malignant diseases. Despite its efficacy, resistance to CDDP remains a significant clinical challenge, often resulting in treatment failure and disease progression. Currently, efforts are underway to unravel the mechanisms of CDDP drug resistance in cancer treatment. The elevated presence of glutathione S-transferase pi-1 (GSTP1-1) within tumor cells plays a pivotal role in the development of resistance toward the effects of CDDP. GSTP1-1 contributes to detoxification by conjugating glutathione (GSH) to CDDP, reducing its accumulation and effectiveness in the tumor cells. In this study, the efficacy of gliquidone, an antidiabetic drug, demonstrated its capacity to impede tumor cell proliferation in both lung cancer A549 cell lines and A549/CDDP cell lines. This was achieved by suppressing the expression of GSTP1-1 within tumor cells (IC₅₀: 16.8 ± 0.8 μM). Furthermore, through the establishment of a nude mouse model featuring lung adenocarcinoma A549/CDDP cell transplantation tumors, gliquidone demonstrated a significant therapeutic effect on the mice tumors, while avoiding discernible side effects. These findings suggest that gliquidone could potentially be repurposed as an adjunct therapy in CDDP-resistant lung cancer.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/7133198","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142664837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TH-302: A Highly Selective Hypoxia-Activated Prodrug for Treating PARP Inhibitor–Resistant Cancers","authors":"Xiaobo Cheng,&nbsp;Jing Xu,&nbsp;Fanying Meng,&nbsp;Tianyang Qi,&nbsp;Xiaotong Wang,&nbsp;Ranran Chai,&nbsp;Chong Lu,&nbsp;Guanqin Jin,&nbsp;Kewei Zheng,&nbsp;Xing Liu,&nbsp;Yizhi Wang,&nbsp;Xiaohong Cai,&nbsp;Zhaoqiang Lu,&nbsp;Jibing Yu,&nbsp;Meizhen Ruan,&nbsp;Jinwei Fan,&nbsp;Wei Qin,&nbsp;Qunhui Huang,&nbsp;Yanjun Zhang,&nbsp;Anrong Li,&nbsp;Jianxin Duan,&nbsp;Yu Kang","doi":"10.1155/2024/3809926","DOIUrl":"https://doi.org/10.1155/2024/3809926","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Poly (ADP-ribose) polymerase (PARP) inhibitor has been widely used in ovarian cancer patients carrying BRCA mutations. However, resistance to PARP inhibitor is present in some patients, and no effective treatment is available for these patients. TH-302 is a hypoxia-activated prodrug, which releases the bis-DNA alkylator bromo-isophosphoramide mustard (Br-IPM) under hypoxic condition. The present study aims to determine whether TH-302 is effective in treating PARP inhibitor resistance.</p>\u0000 <p><b>Methods:</b> The in vitro cytotoxicity of TH-302 was assessed by short-term proliferation assay (50% inhibitory concentration, IC₅₀) or long-term clonogenic assay (90% inhibitory concentration, IC₉₀) under various oxygen concentrations. In vivo efficacy of TH-302 was assessed in PARP inhibitor resistance, partially responsive and sensitive patient-derived xenograft (PDX) or cell line–derived xenograft (CDX) models. Antitumor activity via homologous recombination (HR) pathway for TH-302 was evaluated using DLD1 BRCA2 knockout cell line and BRCA/RAD51D deleterious mutant PDX/CDX models. Breaks of double-strand DNA and hypoxia fraction in tumors were determined by gamma histone 2AX (γH2AX) and pimonidazole immunohistochemistry in H460 CDX model following treatment.</p>\u0000 <p><b>Results:</b> Cytotoxicity was significantly enhanced under hypoxia in 12 human cancer cell lines including four ovarian cancer cell lines. The cytotoxicity was 70 times higher in human colon cancer cell line with BRCA2 knock out compared to wild type under hypoxia following TH-302 treatment. γH2AX staining revealed that the cytotoxicity of TH-302 was associated with DNA damage. In addition, administration of TH-302 with olaparib led to better antitumor activities than either single drug/prodrug in olaparib-resistant PDX models.</p>\u0000 <p><b>Conclusion:</b> TH-302 exhibits hypoxia-dependent cytotoxicity across a wide range of human cancer cell lines, and may be a drug candidate to treat ovarian cancer, bladder cancer, and pancreatic cancer with HR deficiencies with or without resistance to PARP inhibitor. TH-302 may be effective in recurrent epithelial ovarian cancer (EOC) with homologous recombination deficiency (HRD) or in EOC patients resistant to PARP inhibitors.</p>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2024 1","pages":""},"PeriodicalIF":2.1,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/3809926","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142555425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}